Stifel Financial Corp Has $1.95 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Stifel Financial Corp grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 33.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 88,478 shares of the company's stock after acquiring an additional 22,087 shares during the period. Stifel Financial Corp's holdings in Teva Pharmaceutical Industries were worth $1,950,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Oarsman Capital Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $29,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Ameliora Wealth Management Ltd. acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $66,000. IFP Advisors Inc increased its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC raised its stake in Teva Pharmaceutical Industries by 27.7% in the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $16.40 on Tuesday. The company's 50 day moving average price is $15.10 and its two-hundred day moving average price is $17.48. The firm has a market capitalization of $18.59 billion, a P/E ratio of -11.31, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.